MedTrace Logo

Assessing Vulnerability and Outcomes of Intracranial Atherosclerotic Plaques

NCT07156344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3849

Last updated 2025-09-05

No results posted yet for this study

Summary

This prospective cohort study aims to establish a large-scale cohort for primary stroke prevention in asymptomatic intracranial atherosclerosis (ICAS). Objectives include: characterizing risk factor and stenotic artery distributions; determining optimal TCD screening sentinel arteries; observing plaque progression/regression via HR-MRI; establishing vulnerable plaque evaluation systems through stroke event follow-up; and developing cognitive decline prediction models integrating hemodynamic parameters. All procedures (TCD, HR-MRI, neuropsychological assessments) are routine clinical examinations with minimal risk. Participation is voluntary. Initial TCD and qualifying HR-MRI scans incur standard fees; all follow-up imaging and neuropsychological assessments post-enrollment are provided free of charge.

Conditions

  • Asymptomatic Intracranial Atherosclerotic Stenosis Patients

Interventions

DIAGNOSTIC_TEST

Progression and Outcome of Intracranial Atherosclerosis

"Progression and Outcome of Intracranial Atherosclerosis" is the primary endpoint; all others are secondary endpoints. Stroke defined as any stroke and new ipsilateral stroke (including ischemic and hemorrhagic stroke) associated with vascular stenosis.

Sponsors & Collaborators

  • The People's Hospital of Liaoning Province

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Jilin Electric Power Hospital

    collaborator UNKNOWN

  • Jilin city central hospital

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07156344 on ClinicalTrials.gov